Efficacy and resistance mechanisms of LD-aminopterin in psoriasis
LD-氨基蝶呤治疗银屑病的疗效及耐药机制
基本信息
- 批准号:9188625
- 负责人:
- 金额:$ 49万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2014
- 资助国家:美国
- 起止时间:2014-08-01 至 2019-01-31
- 项目状态:已结题
- 来源:
- 关键词:Adverse effectsAffectAgitationAminopterinAreaBiological AssayBiological Response Modifier TherapyCanis familiarisCaringChronicChronic small plaque psoriasisClinicClinicalClinical ResearchCoupledCyclic GMPDHFR geneDNADisease remissionDisorientationDoseEffectivenessFailureFatigueFeelingFolic Acid AntagonistsGeneticHeadacheHealthHepatotoxicityHumanIn VitroInflammationInflammatoryIntestinesIsoenzymesLegal patentLiverMarketingMemory impairmentMethodsMethotrexateMitochondriaMusNuclearOralPatientsPharmaceutical EconomicsPharmaceutical PreparationsPhase II Clinical TrialsPhototherapyPlacebo ControlPlacebosPopulationPricePropertyProtonsPsoriasisReactionRelapseReportingResistanceRestRiskSLC19A1 geneSafetySeveritiesTestingThymidylate SynthaseTimeToxic effectTranslatingUnited StatesUracilbasecellular developmentclinical biomarkerscostenantiomerexperienceimprovedin vivoindexingmeetingsnovelplacebo controlled studypreclinical studyresistance mechanismresponseskin disorderuptake
项目摘要
DESCRIPTION (provided by applicant): Psoriasis is a chronic, genetically influenced, remitting and relapsing scaly and inflammatory skin disorder that affects 1-3% of the world's population, resulting in total annual costs of $5.2 billion in the United States in 2012. Approximately 20% of patients with moderate-to-severe chronic plaque psoriasis require phototherapy and/or a variety of systemic treatments, where methotrexate (MTX) is the mostly widely used oral systemic agent. Despite the relative effectiveness of MTX, as a monotherapy, it does not achieve greater than a 75% reduction in the baseline psoriasis area-and-severity index (PASI 75) in 40% of patients, and fails to achieve remission (i.e. > PASI 90) in 60% of patients. Furthermore, up to 30% of patients with moderate-to-severe plaque psoriasis discontinue oral MTX primarily because of intolerance to the drug. While much effort has been directed to identifying the mechanism behind poor and/or toxic responses to MTX based on genetic factor and quantitation of its active metabolites, the majority of MTX failures remain unexplained. Given the efficacy and safety limitations of MTX and the cost of biologics compared to MTX (~$20,000 vs. $300 per year), there is a clear market opportunity for an improved antifolate with better efficacy and/or safety than MTX, but that is priced between MTX and biologics. LD-Aminopterin (LD-AMT) is a patented composition developed by Syntrix Biosystems that studies indicate has greater cellular uptake (i.e. polyglutamylation to the active metabolites) than MTX, and less liver and CNS toxicity, properties that may translate into better efficacy and/or safety. In addition to identifying LD-AMT as a potential improvement on MTX, gaining a mechanistic understanding of antifolate resistance in general has important clinical implications for treating inflammation with LD-AMT or MTX, by possibly identifying clinical biomarkers to predict optimal response or risk of toxicity in advance of initiating treatment. This U44 Fast-Track proposal aims to advance LD-AMT to the clinic by testing LD-AMT for efficacy in a placebo-controlled phase 2 trial and advancing a novel hypothesis-driven mechanistic explanation for antifolate resistance.
描述(申请人提供):牛皮癣是一种慢性、受遗传影响、缓解和复发的鳞片状和炎症性皮肤病,影响世界人口的1%-3%,导致2012年美国每年的总成本为52亿美元。大约20%的中到重度慢性斑块型银屑病患者需要光疗法和/或各种全身治疗,其中甲氨蝶呤(MTX)是最广泛使用的口服全身用药。尽管MTX相对有效,但作为一种单一疗法,在40%的患者中,它对牛皮癣的基线面积和严重程度指数(PASI 75)的降幅不超过75%,在60%的患者中未能实现缓解(即>;PASI 90)。此外,多达30%的中到重度斑块型牛皮癣患者停止服用MTX,主要是因为对该药物不耐受。虽然基于遗传因素和对MTX活性代谢物的定量,人们已经致力于确定MTX不良和/或毒性反应背后的机制,但大多数MTX失败的原因仍不清楚。考虑到MTX的疗效和安全性限制,以及与MTX相比,生物制品的成本(每年约2万美元对300美元),显然存在比MTX更有效和/或更安全的改良抗叶酸的市场机会,但价格介于MTX和生物制品之间。LD-氨基蝶呤(LD-AMT)是Syntrix BiosSystems公司开发的一种专利组合物,研究表明,与MTX相比,LD-AMT具有更大的细胞摄取(即对活性代谢物的多谷氨酰化),更低的肝脏和中枢神经系统毒性,这些特性可能会转化为更好的疗效和/或安全性。除了确定LD-AMT是MTX的潜在改进外,了解抗叶酸耐药性的一般机制对于使用LD-AMT或MTX治疗炎症具有重要的临床意义,因为它可能在开始治疗之前确定临床生物标记物来预测最佳反应或毒性风险。这项U44快速通道建议旨在通过在安慰剂对照的第二阶段试验中测试LD-AMT的有效性,并提出一种新的假设驱动的抗叶酸抵抗机制解释,将LD-AMT推向临床。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
STUART J KAHN其他文献
STUART J KAHN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('STUART J KAHN', 18)}}的其他基金
A Phase 1 Randomized Single Oral Dose Four Period Cross-Over Study Investigating Omnitram Dose Proportionality and Food Effect in Normal Human Subjects
一项 1 期随机单次口服剂量四期交叉研究,调查 Omnitram 剂量比例和食物对正常人类受试者的影响
- 批准号:
10372803 - 财政年份:2019
- 资助金额:
$ 49万 - 项目类别:
A Phase 1 Randomized Single Oral Dose Four Period Cross-Over Study Investigating Omnitram Dose Proportionality and Food Effect in Normal Human Subjects
一项 1 期随机单次口服剂量四期交叉研究,调查 Omnitram 剂量比例和食物对正常人类受试者的影响
- 批准号:
10029002 - 财政年份:2019
- 资助金额:
$ 49万 - 项目类别:
HLS- A Phase 1 Open-Label Dose-Escalation with Expansion Study of SX-682 in MDS Patients
HLS-SX-682 在 MDS 患者中的 1 期开放标签剂量递增和扩展研究
- 批准号:
9789451 - 财政年份:2018
- 资助金额:
$ 49万 - 项目类别:
A Phase 1 Clinical Trial Evaluating the Novel Small Molecule Immuno-Oncology Antagonist SX-682 Alone and With Pembrolizumab in Metastatic Melanoma
评估新型小分子免疫肿瘤拮抗剂 SX-682 单独使用以及与 Pembrolizumab 联合治疗转移性黑色素瘤的 1 期临床试验
- 批准号:
9348033 - 财政年份:2017
- 资助金额:
$ 49万 - 项目类别:
A Phase 1 Clinical Trial Evaluating the Novel Small Molecule Immuno-Oncology Antagonist SX-682 Alone and With Pembrolizumab in Metastatic Melanoma
评估新型小分子免疫肿瘤拮抗剂 SX-682 单独使用以及与 Pembrolizumab 联合治疗转移性黑色素瘤的 1 期临床试验
- 批准号:
10189528 - 财政年份:2017
- 资助金额:
$ 49万 - 项目类别:
A Phase 1 Clinical Trial Evaluating the Novel Small Molecule Immuno-Oncology Antagonist SX-682 Alone and With Pembrolizumab in Metastatic Melanoma
评估新型小分子免疫肿瘤拮抗剂 SX-682 单独使用以及与 Pembrolizumab 联合治疗转移性黑色素瘤的 1 期临床试验
- 批准号:
9755385 - 财政年份:2017
- 资助金额:
$ 49万 - 项目类别:
Phase II clinical evaluation of Omnitram in neuropathic pain
Omnitram 治疗神经病理性疼痛的 II 期临床评价
- 批准号:
8981655 - 财政年份:2015
- 资助金额:
$ 49万 - 项目类别:
Phase II clinical evaluation of Omnitram in neuropathic pain
Omnitram 治疗神经病理性疼痛的 II 期临床评价
- 批准号:
9317459 - 财政年份:2015
- 资助金额:
$ 49万 - 项目类别:
Efficacy and resistance mechanisms of LD-aminopterin in psoriasis
LD-氨基蝶呤治疗银屑病的疗效及耐药机制
- 批准号:
8792437 - 财政年份:2014
- 资助金额:
$ 49万 - 项目类别:
Overcoming Tramadol Resistance In CYP2D6 Poor Metabolizers
克服 CYP2D6 代谢不良者的曲马多耐药性
- 批准号:
8713969 - 财政年份:2010
- 资助金额:
$ 49万 - 项目类别:
相似海外基金
RII Track-4:NSF: From the Ground Up to the Air Above Coastal Dunes: How Groundwater and Evaporation Affect the Mechanism of Wind Erosion
RII Track-4:NSF:从地面到沿海沙丘上方的空气:地下水和蒸发如何影响风蚀机制
- 批准号:
2327346 - 财政年份:2024
- 资助金额:
$ 49万 - 项目类别:
Standard Grant
BRC-BIO: Establishing Astrangia poculata as a study system to understand how multi-partner symbiotic interactions affect pathogen response in cnidarians
BRC-BIO:建立 Astrangia poculata 作为研究系统,以了解多伙伴共生相互作用如何影响刺胞动物的病原体反应
- 批准号:
2312555 - 财政年份:2024
- 资助金额:
$ 49万 - 项目类别:
Standard Grant
How Does Particle Material Properties Insoluble and Partially Soluble Affect Sensory Perception Of Fat based Products
不溶性和部分可溶的颗粒材料特性如何影响脂肪基产品的感官知觉
- 批准号:
BB/Z514391/1 - 财政年份:2024
- 资助金额:
$ 49万 - 项目类别:
Training Grant
Graduating in Austerity: Do Welfare Cuts Affect the Career Path of University Students?
紧缩毕业:福利削减会影响大学生的职业道路吗?
- 批准号:
ES/Z502595/1 - 财政年份:2024
- 资助金额:
$ 49万 - 项目类别:
Fellowship
Insecure lives and the policy disconnect: How multiple insecurities affect Levelling Up and what joined-up policy can do to help
不安全的生活和政策脱节:多种不安全因素如何影响升级以及联合政策可以提供哪些帮助
- 批准号:
ES/Z000149/1 - 财政年份:2024
- 资助金额:
$ 49万 - 项目类别:
Research Grant
感性個人差指標 Affect-X の構築とビスポークAIサービスの基盤確立
建立个人敏感度指数 Affect-X 并为定制人工智能服务奠定基础
- 批准号:
23K24936 - 财政年份:2024
- 资助金额:
$ 49万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
How does metal binding affect the function of proteins targeted by a devastating pathogen of cereal crops?
金属结合如何影响谷类作物毁灭性病原体靶向的蛋白质的功能?
- 批准号:
2901648 - 财政年份:2024
- 资助金额:
$ 49万 - 项目类别:
Studentship
ERI: Developing a Trust-supporting Design Framework with Affect for Human-AI Collaboration
ERI:开发一个支持信任的设计框架,影响人类与人工智能的协作
- 批准号:
2301846 - 财政年份:2023
- 资助金额:
$ 49万 - 项目类别:
Standard Grant
Investigating how double-negative T cells affect anti-leukemic and GvHD-inducing activities of conventional T cells
研究双阴性 T 细胞如何影响传统 T 细胞的抗白血病和 GvHD 诱导活性
- 批准号:
488039 - 财政年份:2023
- 资助金额:
$ 49万 - 项目类别:
Operating Grants
How motor impairments due to neurodegenerative diseases affect masticatory movements
神经退行性疾病引起的运动障碍如何影响咀嚼运动
- 批准号:
23K16076 - 财政年份:2023
- 资助金额:
$ 49万 - 项目类别:
Grant-in-Aid for Early-Career Scientists